Cellebrite DI Ltd. (CLBT) Bundle
Standing at the intersection of public safety and cutting-edge technology, Cellebrite DI Ltd. - founded in 1999 and headquartered in Petah Tikva, Israel - has built a global footprint with offices in 14 locations and a reputation anchored by its flagship Universal Forensic Extraction Device (UFED), offering law enforcement and enterprise customers tools to collect, review, analyze and manage digital data; publicly traded on NASDAQ as CLBT, the company announced a strategic move to expand its capabilities with the June 2025 agreement to acquire Corellium, and as of December 23, $19.24 per share reflects its market standing while its mission to "Protect and Save Lives, Accelerate Justice and Preserve Privacy," vision of "a safer world where tomorrow can be even better than today," and core values of Integrity, Innovation, Collaboration, Excellence and Customer focus continue to drive product development, investments in R&D, certifications like ISO 9001:2015, and partnerships that accelerate justice through platforms such as Case-to-Closure.
Cellebrite DI Ltd. (CLBT) - Intro
Cellebrite DI Ltd. (CLBT) is a global leader in digital intelligence solutions, delivering hardware, software and services that enable law enforcement agencies and enterprises to collect, review, analyze and manage digital data across mobile, cloud and IoT ecosystems. Founded in 1999 and headquartered in Petah Tikva, Israel, the company has expanded its global footprint with offices in 14 locations worldwide. Cellebrite's flagship product family, including the Universal Forensic Extraction Device (UFED), is widely used for mobile device data extraction and analysis. The company is publicly traded on the NASDAQ under the ticker CLBT; as of December 23, 2025 its stock price is $19.24 USD. In June 2025 Cellebrite announced an agreement to acquire Corellium, a leader in Arm-based virtualization software, to strengthen its digital intelligence and virtualization capabilities.- Founded: 1999
- Headquarters: Petah Tikva, Israel
- Global offices: 14 locations
- Public listing: NASDAQ - CLBT
- Notable product: Universal Forensic Extraction Device (UFED)
- Strategic acquisition: Corellium announced June 2025
- Stock price (12/23/2025): $19.24 USD
| Metric | Detail / Value |
|---|---|
| Founded | 1999 |
| Headquarters | Petah Tikva, Israel |
| Global offices | 14 |
| Flagship product | Universal Forensic Extraction Device (UFED) |
| Public ticker | NASDAQ: CLBT |
| Recent strategic move | Agreement to acquire Corellium (June 2025) |
| Share price (12/23/2025) | $19.24 USD |
- Empower investigators, security teams and enterprises with timely, lawful access to digital evidence and actionable insights to protect communities and organizations.
- Deliver dependable, scalable digital intelligence tools that accelerate investigations while preserving integrity and chain-of-custody.
- Be the global standard for lawful, ethical digital intelligence-enabling safer societies through pervasive, privacy-conscious access to critical digital evidence.
- Integrate cutting-edge virtualization, cloud and AI capabilities (including enhancements from the Corellium agreement) to expand access to new device types and software environments.
- Integrity - commitment to lawful, auditable processes and evidentiary standards.
- Reliability - products engineered for repeatable, defensible results in court and operational environments.
- Innovation - continuous investment in R&D to address emerging device architectures, OS versions and cloud ecosystems.
- Partnership - long-term collaboration with governments, enterprises and the security research community.
- Privacy & Ethics - balancing investigative needs with civil liberties through policy, controls and transparency.
- Product roadmap alignment: prioritize device support breadth (mobile, IoT, cloud) and in-lab virtualization via Corellium to reduce gaps in access to Arm-based environments.
- Operational metrics: maintain chain-of-custody, tool validation and court-admissible processes across deployments globally.
- Market presence: sustain and expand adoption of UFED and complementary platforms across law enforcement and enterprise segments in 14 global offices and through authorized partners.
- Investor signaling: public listing (CLBT) and strategic M&A (Corellium, June 2025) to accelerate capability expansion and long-term revenue diversification.
- Public investors track CLBT share performance and strategic growth initiatives; latest quoted price: $19.24 (12/23/2025).
- Acquisitions like Corellium are positioned to enhance technical moat-supporting higher-value services, labs and virtualization-driven workflows.
- Customers and partners evaluate solutions based on device coverage, legal defensibility, and product lifecycle support-core elements tied directly to Cellebrite's mission and values.
Cellebrite DI Ltd. (CLBT) Overview
Cellebrite's mission is to 'Protect and Save Lives, Accelerate Justice and Preserve Privacy in communities around the world.' This mission guides product design, partnerships, and go-to-market strategy across law enforcement, government, and enterprise customers.- Protect and Save Lives: solutions focused on extracting and analyzing digital evidence rapidly to support time-sensitive investigations and missing-person searches.
- Accelerate Justice: tools and workflows designed to reduce evidence turnaround times and improve courtroom-ready reporting.
- Preserve Privacy: technology and processes that emphasize lawful access, auditability, and minimization of non-consensual data exposure.
| Metric | Value (most recent public disclosure / approximate) |
|---|---|
| Founded | 1999 |
| Public listing | NASDAQ (CLBT), 2021 |
| Global customers | ~7,500+ public safety, government and enterprise customers |
| Geographic reach | 150+ countries |
| Annual revenue (FY, approximate) | ~$350-$380 million (recent fiscal year) |
| R&D investment | ~12-18% of revenue (company trend toward continuous product investment) |
| Employees | ~1,300-1,500 global employees |
| Deployments in public safety | Thousands of agency deployments; used in major national investigations and multinational task forces |
- Forensics and extraction: device-level acquisition for smartphones, tablets and IoT to surface critical evidence quickly.
- Analytics and intelligence: linking, timeline construction and AI-assisted triage to accelerate suspect leads and case progress.
- Cloud and lawful access: scalable cloud capabilities for court-authorized data collection with audit trails to preserve privacy and chain of custody.
- Case management and court readiness: standardized reporting, evidence export and expert support to shorten prosecution timelines.
- Operational tempo: average case-processing time reductions reported by agencies after adoption (typically measured in days to weeks).
- Auditability: built-in logging and role-based access to ensure investigations maintain legal and privacy safeguards.
- Partnerships: collaborative programs with national agencies, NGOs and academic institutions to improve public-safety outcomes.
- Compliance: product certifications and legal review processes to align deployments with privacy and human-rights considerations.
Cellebrite DI Ltd. (CLBT) - Mission Statement
Cellebrite envisions 'a safer world where tomorrow can be even better than today.' This vision encapsulates a forward-looking commitment to continuous improvement in digital intelligence solutions and underpins the company's strategic roadmap toward accelerating justice and public safety.- A commitment to public safety through innovative digital intelligence tools.
- Continuous product and process improvement to make investigations faster and more accurate.
- End-to-end platforms (Case-to-Closure, C2C) to shorten investigative timelines and improve outcome rates.
- Long-term orientation: solutions designed to scale with evolving digital ecosystems and threats.
- Product strategy centers on integrated platforms (Cellebrite Provisioning, UFED, Physical Analyzer, and C2C orchestration).
- Investment focus: R&D-driven innovation to maintain leadership in mobile and cloud data extraction, analysis, and case management.
- Customer focus: law enforcement, federal agencies, and enterprise security teams to improve case throughput and conviction-supporting evidence integrity.
| Metric | Value |
|---|---|
| Founded | 1999 |
| Headquarters | Petah Tikva, Israel (global offices) |
| Public (Ticker) | NASDAQ: CLBT (public since 2021) |
| Approx. Employees | ~1,100 |
| Recent Fiscal Year Revenue | $234.2 million |
| Recent Fiscal Year Net (Loss)/Income | ($55.6) million |
| R&D Spend (most recent FY) | $67.5 million |
| Key product platform | Case-to-Closure (C2C) - end-to-end investigative workflow |
- Faster case resolution: integrated C2C workflows reduce average investigative cycle times (customer-reported improvements range from 20%-50% depending on deployment and case type).
- Evidence throughput: digital evidence ingestion and automated correlation increase analyst capacity per investigator.
- Adoption metrics: growing government and enterprise deployments across 100+ countries, reflecting global alignment with the 'safer world' mission.
- Scale platform interoperability - build connectors to cloud providers, messaging platforms, and enterprise systems to keep pace with data source proliferation.
- AI/ML integration - accelerate automated triage, link analysis, and predictive prioritization to reduce manual workload.
- Training & certification - expand capability-building for customers to maximize public-safety impact from technology investments.
Cellebrite DI Ltd. (CLBT) - Vision Statement
Cellebrite DI Ltd. (CLBT) envisions enabling a safer, more transparent digital world by providing lawful, ethical, and industry-leading digital intelligence solutions that empower governments, enterprises, and service providers to act decisively on digital evidence. The vision is rooted in measurable commitments to integrity, innovation, collaboration, excellence, and customer focus - each backed by company-scale metrics and investments that guide strategy and operations.- Integrity: Cellebrite maintains strict compliance programs and independent audits to ensure ethical conduct across global operations, with third-party certifications and compliance coverage across 100% of major product lines.
- Innovation: Sustained R&D investment drives product leadership - historically allocating roughly one-fifth of annual revenue to research and development to accelerate feature parity and new product pipelines.
- Collaboration: Global partnerships and joint training initiatives continue to expand, with partnerships in 60+ countries and a growing network of certified training centers.
- Excellence: Quality management systems and certifications such as ISO 9001:2015 underpin product development and service delivery standards.
- Customer focus: High customer satisfaction and retention rates reflect deep customer engagement and tailored solutions for law enforcement, government agencies, and enterprise clients.
| Metric | Value / Target | Context |
|---|---|---|
| Founding Year | 1999 | Established technology and forensic expertise |
| Public Listing | 2021 (ticker: CLBT) | SPAC merger accelerated capital markets access |
| Annual Revenue (approx.) | ~$420 million (FY2023 estimate) | Revenue growth driven by recurring software subscriptions and services |
| R&D Spend | ~20% of revenue (targeted/typical) | Significant reinvestment to sustain product leadership |
| Employees | ~1,600-1,800 globally | Cross-functional teams in engineering, services, and support |
| Global Partnerships | 60+ countries | Includes OEMs, channel partners, and training centers |
| Quality Certification | ISO 9001:2015 | Applies to key product and service processes |
| Customer Satisfaction | ~90%+ (survey-based) | High retention and repeat purchase rates |
- Integrity - embedding ethical frameworks, transparent governance, and compliance monitors into contracts, product policies, and go-to-market activity.
- Innovation - delivering a pipeline of capabilities across mobile, cloud, and AI-assisted analytics, and maintaining rapid release cadences for threat and device support.
- Collaboration - scaling global training programs and partner enablement to increase certified practitioners and improve time-to-value for customers.
- Excellence - pursuing high-quality standards, independent certifications, and continuous process improvement across engineering and services.
- Customer focus - using customer success metrics and NPS-style feedback loops to prioritize roadmap items and service SLAs.
- Expand recurring revenue mix via subscription and SaaS adoption to stabilize ARR and improve gross margins.
- Grow certified partner and training footprint to accelerate deployment and compliance adoption worldwide.
- Maintain or increase R&D investment (~20% of revenue) to support device coverage, cloud connectors, and AI analytics.
- Retain high customer satisfaction (>90%) through improved support SLAs and expanded professional services capacity.

Cellebrite DI Ltd. (CLBT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.